{"id":406311,"date":"2020-12-29T16:04:17","date_gmt":"2020-12-29T21:04:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=406311"},"modified":"2020-12-29T16:04:17","modified_gmt":"2020-12-29T21:04:17","slug":"oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PRINCETON, N.J., Dec.  29, 2020  (GLOBE NEWSWIRE) &#8212; Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 39<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET, and host investor meetings.<\/p>\n<p align=\"justify\">To access the live webcast, please visit the \u201cInvestors and News\u201d section of the Oyster Point Pharma website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W8y7cEatVlV0H1yI5Efk9Xu74lMezw7dBdJ5lf1fjEK_sOYjNwygOXCDdiD6RVPk7FfISVEdC9dFFmMiTy856dmQJbrq6J_jHRBZEBlZtElXQV6sp0ny6CLCeayua2wqQM0-1Nf9aYHBlk7ipHXrTN_HE-rCVPhhCfLFMZVGv81qIFd4wkjaBl8MV4_wLKadZ2wTfMUrAG-s8SREbJ4BVJU_oKGEB7W4I-M9ENRkCqbxKSqRQf5G54BWtleHTOYy6Dz2MIyo47yz13HmWayPWhlJxLdbvhLp3Q6Ob81uOKudkU_VSVssKdj_j5ujot2w\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/investors.oysterpointrx.com\/<\/a>.<\/p>\n<p>\n        <strong>About Oyster Point Pharma, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma\u2019s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.\u00a0OC-01 (varenicline) nasal spray is an investigational new drug and has not been approved for any indication in any country. The safety and efficacy of OC-01 (varenicline) nasal spray have not previously been established.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\u00a0<br \/>Tim McCarthy\u00a0<br \/>LifeSci\u00a0Advisors, LLC\u00a0<br \/>(212) 915-2564\u00a0<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wPVe-rN0GwugehqYpdyniLra2HZle2gPQ_dMWpebFWsz83aAF4WqWIeLY1T-LcQR-f0wUrSMzOw6-x553-bX_bjYwz_GF5OkiEEcuea56TiSDYz_qMbEHiC3-ttvJ0kG\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@oysterpointrx.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong>\u00a0<br \/>Sheryl Seapy<br \/>W2O Group\u00a0<br \/>(213) 262-9390\u00a0<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JcvANARmsPXFPz1vUSvCyHVEGKaU02rv01F-13D9SLAIRC3MJIFCHDGT3t35u4tPPxZjA68w5Z7ELAvolFDvb-tE5kN83gN39SlX3CEVsvM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sseapy@w2ogroup.com<\/a><\/u><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b21e9910-51b4-4a32-bb2c-8d5bdb12a6b1\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) &#8212; Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET, and host investor meetings. To access the live webcast, please visit the \u201cInvestors and News\u201d section of the Oyster Point Pharma website at\u00a0https:\/\/investors.oysterpointrx.com\/. About Oyster Point Pharma, Inc. Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma\u2019s lead product candidate, OC-01 nasal spray, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-406311","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) &#8212; Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET, and host investor meetings. To access the live webcast, please visit the \u201cInvestors and News\u201d section of the Oyster Point Pharma website at\u00a0https:\/\/investors.oysterpointrx.com\/. About Oyster Point Pharma, Inc. Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma\u2019s lead product candidate, OC-01 nasal spray, &hellip; Continue reading &quot;Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-29T21:04:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2020-12-29T21:04:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":258,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=\",\"datePublished\":\"2020-12-29T21:04:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) &#8212; Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 10:50 a.m. ET, and host investor meetings. To access the live webcast, please visit the \u201cInvestors and News\u201d section of the Oyster Point Pharma website at\u00a0https:\/\/investors.oysterpointrx.com\/. About Oyster Point Pharma, Inc. Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma\u2019s lead product candidate, OC-01 nasal spray, &hellip; Continue reading \"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-29T21:04:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference","datePublished":"2020-12-29T21:04:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":258,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/","name":"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=","datePublished":"2020-12-29T21:04:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExODQ5MCMzODk4NzgyIzIxODgyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oyster-point-pharma-to-participate-in-the-39th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406311","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=406311"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/406311\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=406311"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=406311"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=406311"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}